ClinicalTrials.gg
CompletedNCT05512819Updated Dec 15, 2025

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 42 Days to 84 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
42 Days to 84 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
12th of 19
541 · median 668
Started
2022
with 2 others
Phase 3
14 of 19
1 open now
Registered
13th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 12th largest by enrollment, is one of 3 that started in 2022, is one of 14 in phase 3, and was the 13th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 84 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers.

This study is enrolling participants who are:

  • Born after at least 36 weeks of pregnancy and about 2 months of age at the time of entering the study
  • Have a bodyweight of at least 3 kg

Participants will receive either the study vaccine (20vPnC) or a licensed vaccine (13vPnC) as a 4-dose schedule as a shot in the muscle. Participants will receive Dose 1 on study day 1. Dose 2 will be given 28-70 days after Dose 1, and Dose 3 will be given 28-70 days after Dose 2. Dose 4 will be given at 365-455 days (approximately 12-15 months) of age.

Participation in the study will take approximately 15 months, during which participants will come to the study clinic for 6 times. The study team will ask questions about the participant's health and take some blood samples during the visit.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 84 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants born at ≥36 weeks of gestation and approximately 2 months of age at the time of consent
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study
  • Weight of 3.0 kg or greater at the time of randomization

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 13vPnC, 20vPnC, or any other diphtheria toxoid-containing vaccine.
  • Major known congenital malformation or serious chronic disorder
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study
  • Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt through study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine (20vPnC)

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine (13vPnC)

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants in India and Taiwan with local reactions (redness, swelling, and pain at the injection site), separately by country

    Prompted local reactions after each dose

    Time frame: Day 7

  2. Percentage of participants in India and Taiwan with systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability), separately by country

    Prompted systemic reactions after each dose

    Time frame: Day 7

  3. Percentage of participants in India and Taiwan with adverse events (AEs) from Dose 1 through 1 month after Dose 3 in each group, separately by country

    Adverse events occurring from Dose 1 to 1 month after Dose 3 in each group

    Time frame: Dose 1 to 1 month after Dose 3

  4. Percentage of participants from India and Taiwan with AEs from Dose 4 through 1 month after Dose 4 in each group, separately by country

    Adverse events occurring from Dose 4 to 1 month after Dose 4 in each group

    Time frame: Dose 4 to 1 month after Dose 4

  5. Percentage of participants in India and Taiwan with SAEs from Dose 1 through 1 month after Dose 4 in each group, separately by country

    SAEs occurring up to 1 month after Dose 4 in each group

    Time frame: Dose 1 to 1 month after Dose 4

  6. GMCs of serotype-specific IgG concentrations in Indian participants 1 month after Dose 4 in each vaccine group

    IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Indian participants only

    Time frame: 1 month after Dose 4

Secondary outcomes

  1. Geometric mean concentrations (GMCs) of serotype-specific IgG concentrations 1 month after Dose 3 in each vaccine group, separately by country

    IgG GMCs for the 20vPnC serotypes 1 month after Dose 3

    Time frame: 1 month after Dose 3

  2. Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentration for the 20vPnC serotypes at approximately 1 month after Dose 3 in each vaccine group, separately by country

    IgG concentrations for 20vPnC serotypes 1 month after Dose 3

    Time frame: 1 month after Dose 3

  3. GMCs of serotype-specific IgG concentrations in Taiwanese participants 1 month after Dose 4 in each vaccine group

    IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Taiwanese participants only

    Time frame: 1 month after Dose 4

  4. Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentrations for the 20vPnC serotypes at approximately 1 month after Dose 4 in each vaccine group, separately by country

    IgG concentrations for 20vPnC serotypes 1 month after Dose 4

    Time frame: 1 month after Dose 4

07

Study locations

11 sites
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • BGS Global Institute of Medical Sciences (BGSGIMS)
    Bangalore, Karnataka 560060, India
  • Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
    Pune, Maharashtra 411043, India
  • Maulana Azad Medical College and Associated with Lok Nayak Hospital
    New Delhi, National Capital Territory of Delhi 110002, India
  • Jawahar Lal Nehru Medical College
    Ajmer, Rajasthan 305001, India
  • Institute of Child Health
    Kolkata, West Bengal 700017, India
  • Hsinchu Mackay Memorial Hospital
    Hsinchu, Hsinchu 30071, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 407219, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Sep 2025, 36 months.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 36 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 23, 2022
StartActual
Sep 16, 2022
Primary completionActual
Sep 20, 2025
CompletionActual
Sep 20, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05512819
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Sep 16, 2022
Primary completion
Sep 20, 2025
Completion
Sep 20, 2025
Last update
Dec 15, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion